+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet

Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet

Managed Care 27(1): 29

Because physicians and health plan members both value choice, the current weak market for Inflectra and Renflexis could be a passing phase.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 052195185

Download citation: RISBibTeXText

PMID: 29369768

Related references

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Preference and Adherence 11: 519-530, 2017

Comparisons of a self-report rheumatoid arthritis disease activity index (RADAI) joint count to American College of rheumatology (ACR) core data set measures for rheumatoid arthritis (RA). 2007

Biosimilars: implications for rheumatoid arthritis therapy. Current Opinion in Rheumatology 29(3): 260-268, 2017

SAT0460Patient self-report joint count, rheumatoid arthritis disease activity index (RADAI), on a multidimensional health assessment questionnaire (MDHAQ) is informative in patients with rheumatic diseases other than rheumatoid arthritis:. Annals of the Rheumatic Diseases 71(Suppl 3): 628.1-628, 2013

Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Review of Clinical Immunology 11 Suppl 1: S43-S52, 2016

The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Review of Clinical Immunology 10(8): 981-983, 2015

The filament-nonfilament count in chronic arthritis; an aid in the differentiation of rheumatoid arthritis and osteo-arthritis. Jour Amer Med Assoc 100(9): 654-656, 1933

Likelihood of use and perception towards biosimilars in rheumatoid arthritis: a global survey of rheumatologists. Clinical and Experimental Rheumatology 34(1 Suppl 95): S9-11, 2016

Biosimilars Versus Brands for Rheumatoid Arthritis: Eu5 Payers and Prescribers Place their Bets. Value in Health 17(7): A325, 2014

Anti-Tnf Biosimilars Indicated for Rheumatoid Arthritis are Increasingly Available in Europe: How Do Payers and Key Stakeholders Perceive Them?. Value in Health 17(7): A388, 2014

AB0237Joints count in rheumatoid arthritis: a correlation study between 3 clinicians and ultrasound joints count and the impact on disease activity. Annals of the Rheumatic Diseases 72(Suppl 3): A859.2-A859, 2013

Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. Best Practice and Research. Clinical Rheumatology 29(4-5): 543-549, 2016

Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. Biodrugs 31(5): 447-459, 2017

SAT0094Relationship between the Duration of Rheumatology Practice Experience and Likelihood of Use and Perception towards Biosimilars in Rheumatoid Arthritis Arena. Annals of the Rheumatic Diseases 73(Suppl 2): 624.2-624, 2014

Likelihood of Use and Perception Towards Biosimilars in Rheumatoid Arthritis Arena: Survey of Rheumatologists in European Union, Brazil, Japan and China. Value in Health 16(7): A388-A389, 2013